News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Job Trends
Alnylam Pharmaceuticals to Cut 20-30 Pct Jobs After Novartis AG Ends Partnership
September 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sept 23 (Reuters) - Alnylam Pharmaceuticals Inc (ALNY.O) said it will be cutting 25-30 percent of its workforce due to the completion of a deal with Novartis (NOVN.VX).
Twitter
LinkedIn
Facebook
Email
Print
Job creations
MORE ON THIS TOPIC
Manufacturing
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
November 3, 2026
·
2 min read
·
Nick Paul Taylor
Job Trends
U.S. bioscience jobs up 7% from 2021 to 2025: Report
November 2, 2026
·
2 min read
·
Angela Gabriel
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
·
5 min read
·
Angela Gabriel
Job Trends
8 companies hiring in New York
October 29, 2026
·
1 min read
·
Angela Gabriel
